Repligen corp stock.

Allworth Financial LP raised its holdings in Repligen by 62.7% in Q4 and now owns 262 shares of the biotechnology company’s stock valued at $44,000 after adding another 101 shares to its portfolio. Moreover, Achmea Investment Management B.V. entered into a new position with Repligen in the fourth quarter worth $49,000.On November 14, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $153.79 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 7.92%, and its shares lost 19.47% of their ...Oct 12, 2021 · The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last ... Investors. These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments. [email protected].

11.55%. Overview. Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.

Waltham, Massachusetts 02453. Phone 1 781 250-0111. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue $801.54M. Net Income $185.96M. 2022 Sales Growth 19.54%.

Nov 23, 2023 · The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN ... Shares of the bioprocessing giant Repligen Corporation ( RGEN 4.89%) are glowing green today. Specifically, the biotech's stock was up by as much as 14.9% earlier today. Repligen's shares have ...Listed in 1986. repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

To be eligible to participate in a Job Corps program, applicants must qualify for low-income status under one of five income-related standards: cash assistance, food assistance, earned income, foster child and homelessness.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 12.34% in the past year. Currently, Repligen Corp’s price-earnings ratio is 74.0. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.

Nov 29, 2023 · CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03. Nov 30, 2023 · The latest Repligen stock prices, stock quotes, news, and RGEN history to help you invest and trade smarter. A vertical stack of three evenly spaced horizontal lines. ... Repligen Corp. is a ... Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corp’s ( RGEN) price is currently down 4.66% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $160.14. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 37.23%.305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock analysis for Repligen Corp (R2GE34:B3 Day) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 5.92% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.8. Repligen Corp’s trailing 12-month revenue is $801.3 million with a 19.9% net profit margin. Year-over-year quarterly sales growth most recently was 12.6%.4.08%. $2.65B. CureVac N.V. 1.85%. $1.21B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Nov 13, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. Invest in Repligen Corp on Stash Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process.RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Feb 24, 2023 · Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%.

As of February 13, 2023, Repligen Corp had a $10.2 billion market capitalization, compared to the Medical Equipment, Supplies & Distribution median of $331.8 million. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 2.91% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.0.WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch ...Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Oct 3, 2023 · Repligen Corp stock has a Value Score of 5, Momentum Score of 54 and Estimate Revisions Score of 37. Comparing Agiliti Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. Nov 23, 2023 · The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN ... Oct 23, 2023 · Repligen Corp stock has a Value Score of 5, Growth Score of 82 and Momentum Score of 41. Comparing Premier Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.

Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.

On average, Wall Street analysts predict. that Repligen's share price could reach $188.75 by Nov 2, 2024. The average Repligen stock price prediction forecasts a potential upside of 25.33% from the current RGEN share price of $150.60.

Item 1.01 Entry into a Material Definitive Agreement. On March 4, 2022, Repligen Corporation (the "Company") entered into the Second Supplemental Indenture (the "Second Supplemental Indenture") to the Base Indenture, dated July 19, 2019, as supplemented by that certain First Supplemental Indenture thereto, dated July 19, 2019 …Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.Mar 27, 2023 · During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $157.11. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 36.92%. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp. analyst ratings, historical stock prices, earnings estimates & actuals. RGEN updated stock price target summary.The stock price rose by $0.27, resulting in a percentage change of +0.61%. While this may seem like a small change, it indicates positive momentum for the company’s stock. Looking ahead, Repligen Corporation is scheduled to release its next financial report on February 15, 2024.Shares of the bioprocessing giant Repligen Corporation ( RGEN 4.89%) are glowing green today. Specifically, the biotech's stock was up by as much as 14.9% earlier today. Repligen's shares have ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 63.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp’s Stock Price as of Market Close. As of April 28, 2023, 4:00 PM CST, Repligen Corp’s stock price was $151.63. Repligen Corp is up 4.46% from its previous closing price of $145.15. During the last market session, Repligen Corp’s stock traded between $144.20 and $149.36.

Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Learn more about whether ICU Medical Inc or Repligen Corp is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics. ... AAII Growth Find secular growth stocks poised for outperformance regardless of macroeconomic conditions.Market cap is calculated by taking a company's price per share and multiplying it by the company's total number of shares outstanding. $8.87B. -14.6%. Market Cap / Employee. The market cap of a ... Instagram:https://instagram. unusual stock options activityplaces to sell ipadwindows server coursepenny stocks for day trading ... Stock quotes by finanzen.net · Home · Stocks · Repligen-stock · News for Repligen Repligen. News for Repligen Corp. GlobeNewswire 20d. UPDATE – Repligen ... cherry hill mortgagebest landlord insurance companies usa The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ... dividend return calculator Repligen Corp stock has a Value Score of 4, Growth Score of 82 and Momentum Score of 43. Comparing Medtronic PLC and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.